IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC. AND WATSON LABORATORIES, INC. Petitioners,

v.

MERCK SHARP & DOHME CORP. Patent Owner.

> Case IPR2020-01045 Patent 7,326,708

PETITIONERS' UPDATED MANDATORY NOTICES

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 Pursuant to 37 CFR § 42.8(b)(3), Petitioners Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. hereby file the following Updated Mandatory Notices.¹

A. Each Real Party in Interest (37 C.F.R. § 42.8(b)(1))

The following real parties in interest are identified: Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Watson Laboratories, Inc.

B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))

1. Judicial Matters Involving the '708 Patent

The '708 patent is currently the subject of the following litigations: *Merck Sharp & Dohme Corp. v. Aurobindo Pharma Limited et al.*, 1-20-cv-00949 (D. Del.); *Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories, Inc. et al.*; 1-20-cv-00847 (D. Del.); *Merck Sharp & Dohme Corp. v. Ajanta Pharma Limited et al.*, 1-20-cv-00815 (D. Del.); *Merck Sharp & Dohme Corp. v. Lupin Limited et al.*, 1-20-cv-00776 (D. Del.); *Merck Sharp & Dohme Corp. v. Apotex Inc. et al.*, 1-20-cv-00776 (D. Del.); *Merck Sharp & Dohme Corp. v. Apotex Inc. et al.*, 1-20-cv-00776 (D. Del.); *Merck Sharp & Dohme Corp. v. Apotex Inc. et al.*, 1-20-cv-00776 (D. Del.); *Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Itd. et al.*, 1:19cv-00872 (D. Del.)²; *Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc.* et al., 1:19-cv-00101 (N.D. W.Va.); *Merck Sharp & Dohme Corp. v. Mylan*

¹ Petitioners' mandatory notices are updated to reflect the admission *pro hac vice* of Ms. Rapalino (*see* Paper 15).

² This case was terminated pursuant to a consent judgment entered on February 19, 2020.

Pharmaceuticals Inc. et al., 1:19- cv-01489 (D. Del.); Merck Sharp & Dohme Corp. v. Alvogen Pine Brook f/k/a Alvogen Pine Brook, Inc. et al., 1:19-cv-00310 (D. Del.)³; Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc. et al., 1:19cv-00311 (D. Del.); Merck Sharp & Dohme Corp. v. Sandoz, Inc., 1:19-cv-00312 (D. Del.); Merck Sharp & Dohme Corp. v. Apotex Inc. et al., 1:19-cv-00313 (D. Del.); Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc. et al., 1:19-cv-00314 (D. Del.); Merck Sharp & Dohme Corp. v. Macleods *Pharmaceuticals, Ltd. et al.*, 1:19-cv-00316 (D. Del.)⁴; *Merck Sharp & Dohme Corp.* v. Watson Pharmaceuticals, Inc. et al., 1:19-cv-00317 (D. Del.); Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-00318 (D. Del.); Merck Sharp & Dohme Corp. v. Sun Pharma Global FZE et al., 1:19-cv-00319 (D. Del.); Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Limited et al., 1:19-cv-00320 (D. Del.)⁵; Merck Sharp & Dohme Corp. v. Wockhardt Bio AG et al., 1:19cv-00321 (D. Del.)⁶; Merck Sharp & Dohme Corp. v. Lupin Ltd. et al., 1:19-cv-00347 (D. Del.); Merck Sharp & Dohme Corp. v. Accord Healthcare, Inc., 1:19-cv-

³ This case was terminated pursuant to a consent judgment entered on July 16, 2020.

⁴ This case was terminated pursuant to a consent judgment entered on April 28, 2020.

⁵ This case was terminated pursuant to a consent judgment entered on February 19, 2020.

⁶ This case was terminated pursuant to a consent judgment entered on May 28, 2020.

02192 (D. Del.)⁷; *Merck Sharp & Dohme Corp. v. Apotex Inc.*, 1:20-cv-749 (D. Del.) and *In re Sitagliptin Phosphate ('708 & '921) Patent Litigation*, C.A. No. 19-md-2902-RGA (D. Del.).

2. Administrative Matters

The Public Patent Application Information Retrieval (PAIR) website indicates that there are no related United States patents or pending applications. The '708 patent is currently the subject of the following *inter partes* reviews: *Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-00040 (P.T.A.B.); *Dr. Reddy's Laboratories, Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-01060 (P.T.A.B.); *Sun Pharmaceuticals Industries Ltd. v. Merck Sharp & Dohme Corp.*, IPR2020-01072 (P.T.A.B.).

C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4))

Lead Counsel	Back-Up Counsel
Keith A. Zullow	Sarah J. Fischer
(Reg. No. 37,975)	(Reg. No. 74,104)
GOODWIN PROCTER LLP	GOODWIN PROCTER LLP
The New York Times Building	100 Northern Avenue
620 Eighth Avenue	Boston, MA 02210
New York, NY 10018-1405	sfischer@goodwinprocter.com
kzullow@goodwinprocter.com	Tel: 617-570-3908
Tel: 212-813-8846	Fax: 617-801-8991
Fax: 646-558-4226	

⁷ This case was terminated pursuant to a consent judgment entered on March 27, 2020.

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Case IPR2020-01045 Patent No. 7,326,708

Additional Back-Up Counsel

Emily L. Rapalino (admitted *pro hac vice*) GOODWIN PROCTER LLP 100 Northern Avenue Boston, MA 02210 erapalino@goodwinprocter.com Tel: 617-570-1938 Fax: 617-801-8991

Pursuant to 37 C.F.R. § 42.8(b)(4), counsel for Petitioner agrees to service by mail as detailed above and to electronic service by email to the email addresses above.

Dated: August 20, 2020

<u>/ Keith A. Zullow /</u> Keith A. Zullow (Reg. No. 37,975) Goodwin Procter LLP The New York Times Building 620 Eighth Avenue New York, NY 10018-1405 Tel: 212-813-8800 Fax: 212-355-3333

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.